DK175199B1 - Anvendelse af imexon som immunsuppressivt middel - Google Patents

Anvendelse af imexon som immunsuppressivt middel Download PDF

Info

Publication number
DK175199B1
DK175199B1 DK198903633A DK363389A DK175199B1 DK 175199 B1 DK175199 B1 DK 175199B1 DK 198903633 A DK198903633 A DK 198903633A DK 363389 A DK363389 A DK 363389A DK 175199 B1 DK175199 B1 DK 175199B1
Authority
DK
Denmark
Prior art keywords
imexon
cell
proliferation
imexone
cells
Prior art date
Application number
DK198903633A
Other languages
Danish (da)
English (en)
Other versions
DK363389D0 (da
DK363389A (da
Inventor
Elmar Bosies
Wolfgang Kampe
Dieter Herrmann
Rainer Haag
Uwe Bicker
Original Assignee
Autooncona Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autooncona Pharma Gmbh filed Critical Autooncona Pharma Gmbh
Publication of DK363389D0 publication Critical patent/DK363389D0/da
Publication of DK363389A publication Critical patent/DK363389A/da
Application granted granted Critical
Publication of DK175199B1 publication Critical patent/DK175199B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK198903633A 1988-07-28 1989-07-21 Anvendelse af imexon som immunsuppressivt middel DK175199B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3825667A DE3825667A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum
DE3825667 1988-07-28

Publications (3)

Publication Number Publication Date
DK363389D0 DK363389D0 (da) 1989-07-21
DK363389A DK363389A (da) 1990-01-29
DK175199B1 true DK175199B1 (da) 2004-07-05

Family

ID=6359767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198903633A DK175199B1 (da) 1988-07-28 1989-07-21 Anvendelse af imexon som immunsuppressivt middel

Country Status (14)

Country Link
EP (1) EP0352652B1 (fr)
JP (1) JP2848634B2 (fr)
KR (1) KR0135757B1 (fr)
AT (1) ATE117551T1 (fr)
AU (1) AU619027B2 (fr)
CA (1) CA1333771C (fr)
DE (2) DE3825667A1 (fr)
DK (1) DK175199B1 (fr)
HU (1) HU206827B (fr)
IE (1) IE66680B1 (fr)
IL (1) IL91138A (fr)
PH (1) PH26684A (fr)
PT (1) PT91293B (fr)
ZA (1) ZA895710B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548491A1 (fr) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions anticancereuses synergiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528460A1 (de) * 1975-06-26 1977-01-13 Boehringer Mannheim Gmbh Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE2530398A1 (de) * 1975-07-08 1977-01-27 Boehringer Mannheim Gmbh Organische verbindung
DE2736296A1 (de) * 1977-08-12 1979-02-22 Boehringer Mannheim Gmbh Verwendung von 2-cyan-aziridin und seinen derivaten zur immunstimulierung

Also Published As

Publication number Publication date
PT91293B (pt) 1995-03-01
EP0352652A3 (fr) 1991-09-04
ATE117551T1 (de) 1995-02-15
DE3825667A1 (de) 1990-03-15
IE66680B1 (en) 1996-01-24
HU206827B (en) 1993-01-28
IE892448L (en) 1990-01-28
KR0135757B1 (ko) 1998-04-23
CA1333771C (fr) 1995-01-03
PT91293A (pt) 1990-02-08
AU619027B2 (en) 1992-01-16
HUT52378A (en) 1990-07-28
PH26684A (en) 1992-09-15
DE3825667C2 (fr) 1991-06-27
DE58908926D1 (de) 1995-03-09
DK363389D0 (da) 1989-07-21
EP0352652B1 (fr) 1995-01-25
AU3887789A (en) 1990-02-01
DK363389A (da) 1990-01-29
JP2848634B2 (ja) 1999-01-20
IL91138A0 (en) 1990-03-19
EP0352652A2 (fr) 1990-01-31
ZA895710B (en) 1990-04-25
JPH0288521A (ja) 1990-03-28
IL91138A (en) 1994-10-21
KR900001369A (ko) 1990-02-27

Similar Documents

Publication Publication Date Title
Craft et al. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia.
EP0365044A2 (fr) Utilisation pharmaceutique de (NVA)2-cyclosporine
Albert et al. Bioavailability studies of acetaminophen and nitrofurantoin
EA024071B1 (ru) Способы получения, фармацевтические композиции и способы применения твёрдой формы v вещества xlf-iii-43
DK2167038T3 (en) USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
DK175199B1 (da) Anvendelse af imexon som immunsuppressivt middel
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
CA2672716C (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
US5369119A (en) Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
Horwitz et al. Effects of alpha-methyl-meta-tyrosine intravenously in man
CS198195B2 (en) Process for preparing 4-imino-1,3-diazabicyclo/3,1,0/hexan-2-one
EP0290817B1 (fr) Utilisation d'oxétanocine pour inhiber HIV
CN113413378A (zh) 一种包含绿原酸的药物组合物在制备治疗早期阿尔茨海默病的药物中的用途
CN110818613B (zh) 一种咔唑类化合物及其制备方法与在抗hiv药物中的应用
CN112274642A (zh) Ck2抑制剂在制备类风湿关节炎治疗药物中的应用
JPH05504550A (ja) 免疫抑制剤として有用なピリミジン生合成インヒビター
PT1443943E (pt) Processo para a reacção de alcalóides e uso dos produtos de reacção na preparação de medicamentos
WO1993002692A1 (fr) Procede de lutte contre les infections dues au hiv
RU2775008C1 (ru) Фармацевтическая композиция, обладающая иммуномодулирующей, иммунокорректирующей, иммуносупрессорной, противовирусной, противовоспалительной и онколитической активностями
CN110776456B (zh) 一种咔唑类化合物及其制备方法与在抗hiv药物中的应用
RU2675237C1 (ru) Соединение (6-{ [(1S)-1(5-фтор-4-оксо-3-фенил-3,4-дигидрохиназолин-2-ил)пропил]амино} -9Н-пурин-9-ил)метилацетат как ингибитор p110δ - дельта-изоформы фосфоинозитид-3-киназы (PI3K), способы его получения (варианты) и применения
DE3844655A1 (de) Verwendung von imexon als immunsuppressivum
JPS6232722B2 (fr)
DK164987B (da) Anvendelse af spergualin eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel med transplantationsimmunitetsinhiberende og antiallergisk aktivitet
WO2024086240A1 (fr) Compositions agonistes bêta-adrénergiques et antagonistes muscariniques et procédés d'utilisation

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK